



Attorney Docket No. 9233-46

1646

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ekwuribe et al.
Serial No.: 10/075,097
Filed: February 13, 2002
For: *Methods of Treating Diabetes Mellitus*

Confirmation No. 7253
Group Art Unit: 1646

Commissioner for Patents
Washington, DC 20231

Date: January 10, 2003

RECEIVED
JAN 14 2003
JECH CENTER 1600/2300

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a form PTO-1449, together with a copy of the identified document(s). This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Accordingly, no fee is required. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 50-0220.

Respectfully submitted,

J. Michael Strickland
Registration No. 47,115




20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, DC 20231, on January 10, 2003.

Monica L. Croom
Monica L. Croom

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-46		Serial No. 10/075,097	
LIST OF DOCUMENTS CITED BY APPLICANT							
(Use several sheets if necessary)							
							
				Applicants: Ekwuribe et al.			
				Filing Date: 02/13/02		Group 1646	
U. S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	3,919,411	11/11/75	Glass et al.			
	2.	3,256,153	06/14/66	Heimlech			
	3.	3,868,356	02/25/75	Smyth			
	4.	3,950,517	04/13/76	Lindsay et al.			
	5.	4,003,792	01/18/77	Mill et al.			
	6.	4,044,196	08/23/77	Huper et al.			
	7.	4,087,390	05/02/78	Shields			
	8.	4,093,574	06/06/78	Shields			
	9.	4,100,117	07/11/78	Shields			
	10.	4,179,337	12/18/79	Davis et al.			
	11.	4,229,438	10/21/80	Fujino et al.			
	12.	4,253,998	03/03/81	Sarantakis			
	13.	4,277,394	07/07/81	Fujino et al.			
	14.	4,338,306	07/06/82	Kitao et al.			
	15.	4,348,387	09/07/82	Brownlee et al.			
	16.	4,410,547	10/18/83	Ueno et al.			
	17.	4,469,681	09/04/84	Brownlee et al.			
	18.	4,472,382	09/18/84	Labrie et al.			
	19.	4,554,101	11/19/85	Hopp			
	20.	4,579,730	04/01/86	Kidron et al.			
	21.	4,585,754	04/29/86	Meisner et al.			
	22.	4,622,392	11/11/86	Hong et al.			
	23.	4,684,524	08/04/87	Eckenhoff et al.			
	24.	4,698,264	10/06/87	Steinke			
	25.	4,717,566	01/05/88	Eckenhoff et al.			

RECEIVED
TECH CENTER 1600
JAN 14 2003

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-46	Serial No. 10/075,097
LIST OF DOCUMENTS CITED BY APPLICANT O/P (Use several sheets if necessary) JAN 13 2003 PATENT & TRADEMARK OFFICE				Applicants: Ekwuribe et al.	
				Filing Date: 02/13/02	Group 1646
U.S. PATENT DOCUMENTS (CONT.)					
	26.	4,744,976	05/17/88	Snipes et al.	
	27.	4,772,471	09/20/88	Vanlerberghe et al.	
	28.	4,797,288	01/10/89	Sharma et al.	
	29.	4,839,341	06/13/89	Massey et al.	
	30.	4,840,799	06/20/89	Applegren et al.	
	31.	4,849,405	07/18/89	Ecanow	
	32.	4,917,888	04/17/90	Katre et al.	
	33.	4,935,246	06/19/90	Ahrens	
	34.	4,946,828	08/07/90	Markussen	
	35.	4,957,910	09/18/90	Sutton et al.	
	36.	4,963,367	10/16/90	Ecanow	
	37.	4,994,439	02/19/91	Longenecker et al.	
	38.	5,013,556	05/07/91	Woodle et al.	
	39.	5,055,300	10/08/91	Gupta	
	40.	5,055,304	10/08/91	Makino et al.	
	41.	5,089,261	02/18/92	Nitecki et al.	
	42.	5,093,198	03/03/92	Speaker et al.	
	43.	5,157,021	10/20/92	Balschmidt et al.	
	44.	5,162,430	11/10/92	Rhee et al.	
	45.	5,164,366	11/17/92	Balschmidt et al.	
	46.	5,202,415	04/13/93	Jonassen et al.	
	47.	5,206,219	04/27/93	Desai	
	48.	5,283,236	02/01/94	Chiou	
	49.	5,286,637	02/15/94	Veronese et al.	
	50.	5,292,802	03/08/94	Rhee et al.	
	51.	5,304,473	04/19/94	Belagaje et al.	
	52.	5,308,889	05/03/94	Rhee et al.	
	53.	5,312,808	05/17/94	Shorr et al.	

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


RECEIVED
JAN 14 2003
TECH CENTER 1600
2000-2000


FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-46	Serial No. 10/075,097
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)					
				Applicants: Ekwuribe et al.	
				Filing Date: 02/13/02	Group 1646
U.S. PATENT DOCUMENTS (CONT.)					
54.	5,324,775	06/28/94	Rhee et al.		
55.	5,328,955	07/12/94	Rhee et al.		
56.	5,359,030	10/25/94	Ekwuribe		
57.	5,405,621	04/11/95	Sipos		
58.	5,405,877	04/11/95	Greenwald et al		
59.	5,413,791	05/09/95	Rhee et al.		
60.	5,415,872	05/16/95	Sipos		
61.	5,438,040	08/01/95	Ekwuribe		
62.	5,444,041	08/22/95	Owen et al.		
63.	5,446,091	08/29/95	Rhee et al.		
64.	5,457,066	10/10/95	Frank et al.		
65.	5,461,031	10/24/95	De Felippis		
66.	5,468,478	11/21/95	Saifer et al.		
67.	5,504,188	04/02/96	Baker et al.		
68.	5,506,203	04/09/96	Backstrom et al.		
69.	5,518,998	05/21/96	Backstrom et al.		
70.	5,523,348	06/04/96	Rhee et al.		
71.	5,529,915	06/25/96	Phillips et al.		
72.	5,550,188	08/27/96	Rhee et al.		
73.	5,545,618	08/13/96	Buckley et al.		
74.	5,567,422	10/22/96	Greenwald		
75.	5,606,038	02/25/97	Regen		
76.	5,612,460	03/18/97	Zalipsky		
77.	5,631,347	05/20/97	Baker et al.		
78.	5,637,749	06/10/97	Greenwald		
79.	5,646,242	07/08/97	Baker et al.		
80.	5,650,388	07/22/97	Shorr et al.		
81.	5,658,878	08/19/97	Backstrom et al.		

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


 JAN 14 2003
 TECH CENTER 1600
 USPTO

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number 9233-46	Serial No. 10/075,097
LIST OF DOCUMENTS CITED BY APPLICANT <i>(Use several sheets if necessary)</i>						
					Applicants: Ekwuribe et al.	
					Filing Date: 02/13/02	
U.S. PATENT DOCUMENTS (CONT.)						
82.	5,681,567	10/28/97	Baker et al.			
83.	5,681,811	10/28/97	Ekwuribe			
84.	5,693,609	12/02/97	Baker et al.			
85.	5,693,769	12/02/97	Kahne et al.			
86.	5,700,904	12/23/97	Baker et al.			
87.	5,707,648	01/13/98	Yiv			
88.	5,738,846	04/14/98	Greenwald et al.			
89.	5,747,445	05/05/98	Backstrom et al.			
90.	5,747,642	05/05/98	De Felippis			
91.	5,750,497	05/12/98	Havelund et al.			
92.	5,766,620	06/16/98	Heiber et al.			
93.	5,824,638	10/20/98	Burnside et al.			
94.	5,830,853	11/03/98	Backstrom et al.			
95.	5,830,918	11/03/98	Sportsman et al.			
96.	5,849,860	12/15/98	Hakimi et al.			
97.	5,853,748	12/29/98	New			
98.	5,854,208	12/29/98	Jones et al.			
99.	5,856,451	01/05/99	Olsen et al.			
100.	5,866,538	02/02/99	Norup et al.			
101.	5,874,111	02/23/99	Maitra et al.			
102.	5,898,028	04/27/99	Jensen et al.			
103.	5,902,588	05/11/99	Greenwald et al.			
104.	5,905,140	05/18/99	Hansen			
105.	5,907,030	05/25/99	Shen et al.			
106.	5,922,675	07/13/99	Baker et al.			
107.	5,932,462	08/03/99	Harris et al.			
108.	5,942,248	08/24/99	Barnwell			
109.	5,948,751	09/07/99	Kimer et al.			

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
TECH CENTER 1600
JAN 14 2003

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-46	Serial No. 10/075,097
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)					
				Applicants: Ekwuribe et al.	
				Filing Date: 02/13/02	
U.S. PATENT DOCUMENTS (CONT.)					
110.	5,952,008	09/14/99	Backstrom et al.		
111.	5,952,297	09/14/99	De Felippis et al.		
112.	5,962,267	10/05/99	Shin et al.		
113.	5,968,549	10/19/99	New et al.		
114.	5,969,040	10/19/99	Hallahan et al.		
115.	5,981,709	11/09/99	Greenwald et al.		
116.	5,985,263	11/16/99	Lee et al.		
117.	6,004,574	12/21/99	Backstrom et al.		
118.	6,025,325	02/15/00	Campfield et al.		
119.	6,034,054	03/07/00	De Felippis et al.		
120.	6,043,214	03/28/00	Jensen et al.		
121.	6,051,551	04/18/00	Hughes et al.		
122.	6,063,761	05/16/00	Jones et al.		
123.	6,093,391	07/25/00	Kabanov et al.		
124.	6,113,906	09/05/00	Greenwald et al.		
125.	6,165,976	12/26/00	Backstrom et al.		
126.	6,177,087	01/23/01	Greenwald et al.		
127.	6,191,105	02/20/01	Ekwuribe et al.		
128.	6,200,602	03/13/01	Watts et al.		
129.	6,211,144	04/03/01	Havelund		
130.	6,248,363	06/19/01	Patel et al.		
131.	6,251,856	06/26/01	Markussen et al.		
132.	6,258,377	07/10/01	New et al.		
133.	6,268,335	07/31/01	Brader		
134.	6,306,440	10/23/01	Backstrom et al.		
135.	6,309,633	10/30/01	Ekwuribe et al.		
136.	6,310,038	10/30/01	Havelund		

RECEIVED
JET CENTER 1600 K ST NW
JAN 14 2003

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket Number 9233-46	Serial No. 10/075,097	
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)				RECEIVED <i>JAN 14 2003</i> TECH CENTER 1600/2000 Ekwunife et al.		
				Applicants: <i>Ekwunife et al.</i>	Filing Date: 02/13/02 Group 1646	
U.S. PATENT DOCUMENTS (CONT.)						
137.	6,323,311	11/27/01	Liu et al.			
138.	6,335,316	01/01/02	Hughes et al.			
FOREIGN PATENT DOCUMENTS						
	Document Number	Date	Country	Class	Subclass	Translation Yes No
139.	GB 1 492 997	11/23/77	Great Britain			Yes
140.	EP 0 031 567	07/08/81	EPO			Yes
141.	JP 1 254 699	10/11/89	Japan			No
142.	WO 93/01802	02/04/93	PCT			Yes - abstract
143.	WO 95/09831	04/13/95	PCT			Yes
144.	EP 0 483 465	08/02/95	EPO			Yes - claims
145.	WO 95/30641	11/16/95	PCT			Yes
146.	EP 0 597 007	10/16/96	EPO			Yes
147.	EP 0 621 777	11/09/96	EPO			Yes - claims
148.	WO 98/07745	02/26/98	PCT			Yes
149.	EP 0 797 615	01/13/99	EPO			Yes
150.	WO 99/32134	07/01/99	PCT			Yes
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
151.	Abuchowski, A. and F. F. Davis, "Soluble Polymer-Enzyme Adducts," pp. 368-383, Enzymes as Drugs, J. S. Holcberg, John Wiley, 1981.					
152.	Akiyama, M. et al., "The Synthesis of New Derivatives of 1-.beta.-D-Arabinofuranosylcytosine," Chem. Pharm. Bull., 1978, 26(3): p. 981-984.					
153.	Allcock et al., "Contemporary Polymer Chemistry," 394-403 (2nd. ed., 1991).					
154.	Ansell, S. et al., "Application of Oligo-(14-amino-3,6,9,12-tetraoxatetradecanoic acid) Lipid Conjugates as Steric Barrier Molecules in Liposomal Formulations," Bioconjugate Chem., 10: 653-666 (1999).					
155.	Aoshima, M. et al., "N.sup.4 -Behenoyl-1-.beta.-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent," Cancer Research, 1977, 37: pp. 2481-2486.					
156.	Baker, D. C. et al., "Prodrugs of 9-.beta.-D-Arabinofuranosyladenine. 1. Synthesis and Evaluation of Some 5'-(O-Acyl) Derivatives," J. Med. Chem., 1978, 21(12): pp. 1218-1221.					
157.	Banting et al., "Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report," Can. Med. Assoc. J., 145(10): 1281-1286 (1991).					
158.	Banting, R. G., et al, "Pancreatic Extracts in the Treatment of Diabetes Mellitus," The Canadian Med. Assoc. J. 1992, 12: 141-146.					

EXAMINER
***EXAMINER**

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 9233-46	RECEIVED Serial No. 10/075,097 JAN 14 2003 TECH CENTER 1600/2900
LIST OF DOCUMENTS CITED BY APPLICANT <i>O T P E</i> (Use several sheets if necessary) JAN 13 2003 PATENT & TRADEMARK OFFICE		Applicants: Ekwuribe et al.	
		Filing Date: 02/13/02	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) (CONT.)			
159.	Baudys et al., "Stabilization and Intestinal Absorption of Human Calcitonin," J. Contr. Rel., 39: 145-51 (1996).		
160.	Baudys, M. et al, "Synthesis and Characterization of Different Glycosylated Derivatives of Insulin" Proceed. Intern. Symp. Cont. Rel. Bioactive. Mater., 1992, 19: 210-211.		
161.	Bocci, E. et al., "Pharmacokinetic Properties of Polyethylene Glycol Derivatized Superoxide Dismutase," Pharm. Res. Comm., 1982 14: 113-120.		
162.	Brange, J., "Galenics of Insulin: The Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations," Novo Research Institute, Denmark, 18-100 (1987).		
163.	Brange, J. et al, "Chemical Stability of Insulin. 1. Hydrolytic Degradation During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6): 715-726.		
164.	Brange, J. et al, "Chemical Stability of Insulin. 2. Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations," Pharm. Res., 1992, 9 (6) 727-734.		
165.	Chen et al., "Synthesis and Properties of AMA Amphiphiles," J. Org. Chem., 64: 6870-6873 (1999).		
166.	Chien, Y. W., Novel Drug Delivery Systems, pp. 678-679, Marcell Decker, Inc., New York, N.Y., 1992.		
167.	Conradi, R.A., et al., "The Influence of Peptide Structure on Transport Across Caco-2 Cells," Pharm. Res., 1991, 8(12): 1453-1459.		
168.	Coombes, A.G.A. et al., "Biodegradable Polymeric Microparticles for Drug Delivery and Vaccine Formulation: the Surface Attachment of Hydrophilic Species Using the Concept of Poly(Ethylene Glycol) Anchoring Segments," Biomaterials, 18: 1153-1161 (1997).		
169.	Coudert et al., "A Novel, Unequivocal Synthesis of Polyethylene Glycols," Synthetic Communications, 16(1): 19-26 (1986).		
170.	Delgado et al.; "The Uses and Properties of PEG-Linked Proteins" Critical Reviews in Therapeutic Drug Carrier Systems 9:3.4 249-304 (1992).		
171.	Engel et al.; "Insulin: Intestinal Absorption as Water-in-Oil-in-Water Emulsions" NATURE 219 856-857 (1968).		
172.	Fasano, Alessio; "Innovative strategies for the oral delivery of drugs and peptides" TIBTECH 16 152-157 (1998).		
173.	Forst et al., "New Aspects on Biological Activity of C-peptide in IDDM Patients," Exp. Clin. Endocrinol. Diabetes, 106: 270-276 (1998).		
174.	Gish, D. T. et al., "Nucleic Acids. 11. Synthesis of 5'-Esters of 1-.beta.-D-Arabinofuranosylcytosine Possessing Antileukemic and Immunosuppressive Activity," J. Med. Chem., 1971, 14(12): pp. 1159-1162.		
175.	Gombotz et al., "Biodegradable Polymers for Protein and Peptide Drug Delivery," Bioconjugate Chem., 6: 332-351 (1995).		
176.	Harris, J. Milton, "Laboratory Synthesis of Polyethylene Glycol Derivatives," J. Macromol. Science - Rev. Macromol. Chem. Phys., C25(3): 325-373 (1985).		
177.	Hashimoto et al., "Synthesis of Palmitoyl Derivatives of Insulin and Their Biological Activities," Pharmaceutical Research, 6(2): 171-176 (1989).		
178.	Hostetler, K. Y. et al., "Synthesis and Antiretroviral Activity of Phospholipid Analogs of Azidothymidine and Other Antiviral Nucleosides," The Journal of Biological Chemistry, 1990, 265(11): pp. 6112-6117.		
179.	Hong, C. I. et al., "Nucleoside Conjugates. 7. Synthesis and Antitumor Activity of 1-.beta.-D-Arabinofuranosylcytosine Conjugates of Ether Lipids," J. Med. Chem., 1986, 29: pp. 2038-2044.		

EXAMINER
*EXAMINERDATE CONSIDERED
Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number: 9233-46	RECEIVED Serial No. 10/075,097
LIST OF DOCUMENTS CITED BY APPLICANT		JAN 14 2003	
<p style="text-align: center;">(if several sheets if necessary)</p> 		<p style="text-align: center;">TEC ENTER 600/2000</p>	
		Applicants: Ekwuribe et al.	
		Filing Date: 02/13/02	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) (CONT.)			
180.	Igarashi, R. et al, "Biologically Active Peptides Conjugated with Lecithin for DDS" Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater. 1990, 17 367-368.		
181.	Kemmler et al., "On the Nature and Subcellular Localization of the Proinsulin Converting Enzymes," Federation Proceedings, 30(Abstract 924): 1210Abs (1971).		
182.	Kemmler et al., "Studies on the Conversion of Proinsulin to Insulin: I. Conversion in Vitro with Trypsin and Carboxypeptidase B," The Journal of Biological Chemistry, 246(22) 6786-6791 (November 25, 1971).		
183.	King et al.; "Preparation of Protein Conjugates with Alkoxypropylene Glycols" Int. J. Peptide Protein Res. 16 147-155 (1980).		
184.	M. Maislos et al, "The Source of the Circulating Aggregate of Insulin in Type I Diabetic Patients is Therapeutic Insulin" J. Clin. Invest., 1986, 77: 717-723.		
185.	Nucci, et al. "The Therapeutic Value of Poly(ethylen Glycol)--Modified Proteins" Ac. Drug. Del. Rev. 6: 133-151 1991.		
186.	Oka, K. et al, "Enhanced Intestinal Absorption of a Hydrophobic Polymer-conjugated Protein Drug, Smancs, in an Oily Formulation" Pharm. Res., 1990, 7 (8): 852-855.		
187.	Patel et al. "Oral Administration of Insulin By Encapsulation Within Liposomes" FEBS Lett. 62(1) 60-63 1976.		
188.	Price, JC, <i>Polyethylene Glycol</i> , 355-361.		
189.	Ratner, R. E. et al, "Persistent Cutaneous Insulin Allergy Resulting from High-Molecular Weight Insulin Aggregates," Diabetes, 1990, 39: 728-733.		
190.	Robbins, D. C. et al, "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients" Diabetes, 1987, 36: 838-841.		
191.	Russell-Jones, G. J. "Vitamin B12 Drug Delivery", Proceed. Intern. Symp. Control. Rel. Bioactive. Mater., 1992, 19: 102-103.		
192.	Saffran et al. "A Model for the Study of the Oral Administration of Peptide Hormones" Can J Biochem 57 548-553 1979.		
193.	Saffran, M. et al, "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science, 1986, 233: 1081-1084.		
194.	Santiago, N. et al, "Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres," Proceed. Intern. Symp. Cont. Rel. Bioactive. Mater., 1992, 19: 116-117.		
195.	Savva et al., "Effect of PEG Homopolymer and Grafted Amphiphilic PEG-Palmityl on the Thermotropic Phase Behavior of 1,2-Dipalmitoyl-SN-Glycero-3-Phosphocholine Bilayer," Journal of Liposome Research, 9(3): 357-365 (1999).		
196.	Shichiri et al.; "Enteral Absorption of Water-in-Oil-in-Water Insulin Emulsions in Rabbits" Diabetologia 10 317-321 (1974).		
197.	Szleifer, I. et al., "Spontaneous Liposome Formation Induced by Grafted Poly(Ethylene Oxide) Layers: Theoretical Prediction and Experimental Verification," Proceedings of the National Academy of Sciences of the United States of America, 95(3): 1032-1037 (Feb. 3, 1998).		
198.	Taniguchi, T. et al, "Synthesis of Acetyl Lysozyme and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats" Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater., 1992, 19: 104-105.		
199.	Tyle, Praveen, "Iontophoretic Devices for Drug Delivery," Pharmaceutical Research 3(6): 318-326 (1986).		

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EXAMINER

***EXAMINER**

DATE CONSIDERED

***EXAMINER** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.